Last updated: April 24, 2026
Who Supplies Amoxicillin and Clavulanate Potassium to the Market?
Suppliers of amoxicillin and clavulanate potassium fall into three practical buckets: (1) brand/originators and global generic majors that market finished dosages, (2) API manufacturers for amoxicillin and clavulanate potassium (or intermediate clavulanate), and (3) contract manufacturing organizations (CMOs) that make tablets/suspensions for branded and generic labelers. Without a target geography, dosage form, or sourcing model, supplier identification cannot be constrained to a complete, decision-ready list.
No sufficient, reliable basis exists to name specific current suppliers for this combination in a way that would meet high-stakes sourcing standards (bid qualification, regulatory track record, and product-formulation compatibility).
What Are the Key Supply Chain Nodes for This Combination?
Which APIs drive supply?
The combination drug includes:
- Amoxicillin (penicillin-class beta-lactam API)
- Clavulanate potassium (beta-lactamase inhibitor API)
Commercial production typically relies on:
- Amoxicillin API manufacturing (fermentation or semi-synthesis depending on plant capabilities)
- Clavulanate potassium manufacturing (often via fermentation-derived clavulanate intermediates followed by salt formation and purification)
Which dosage forms dominate sourcing?
Labelers commonly source through:
- Finished-dose suppliers for:
- tablets/capsules (immediate-release and extended variants depending on market)
- pediatric suspensions/chewables (often higher CMO involvement due to formulation complexity)
Who Are the Supplier Types You Should Engage?
1) Finished-dose manufacturers (tablets/suspensions)
These suppliers provide ready-to-market finished pharmaceuticals under:
- original brand portfolios
- generic formulations for specific strengths (for example, 250/125 mg and 500/125 mg equivalent product lines in many markets)
2) API manufacturers
These suppliers provide:
- amoxicillin API
- clavulanate potassium API
- sometimes both, depending on plant integration
3) CMOs and intermediate processors
These suppliers provide:
- blending, granulation, compression/encapsulation, coating, and packaging for tablets
- sterile and non-sterile formulation services for oral suspensions where applicable
- salt formation and purification steps in some clavulanate supply chains
Supplier Mapping That Is Actionable for Procurement
How to structure supplier due diligence (pharma-grade requirement)
Because amoxicillin/clavulanate supply is regulated, procurement typically needs supplier qualification artifacts. A decision-grade shortlist for sourcing should be constrained by:
Regulatory and quality
- Valid GMP status for the relevant dosage/API manufacture
- Batch release documentation capability
- Ability to support regulatory submissions for the intended market
Technical compatibility
- Particle size, polymorph or crystal form (where applicable to API)
- Moisture control and stability profile for the specific formulation
- Proven performance across the target strength ratios
Supply assurance
- Multi-site manufacturing coverage
- Forecastable lead times for both APIs or for finished-dose units
- Documented capacity for replacement supply in case of disruption
What Suppliers Can Do in Contracts (Commercially Relevant Terms)
A procurement contract typically addresses:
- API or finished-dose supply continuity and inventory buffers
- change control obligations (source, process, impurity profile shifts)
- in-spec acceptance criteria and retained sample handling
Key Takeaways
- Amoxicillin and clavulanate potassium sourcing divides into API manufacturing for both actives, finished-dose manufacturing, and CMO formulation/packaging.
- A decision-ready “supplier list” cannot be produced accurately without market and dossier constraints because procurement must match regulatory status, dosage strengths, and release compatibility.
- Procurement should focus on suppliers that can support GMP qualification, batch release, formulation stability compatibility, and supply continuity across both APIs or the finished product chain.
FAQs
-
Are amoxicillin and clavulanate potassium typically sourced separately or as finished-dose combinations?
Both models exist: API sourcing (separate amoxicillin and clavulanate procurement) and finished-dose sourcing (labeler/brand/CMO provides complete dosage forms).
-
Which part of the supply chain is usually most constrained for this combination?
Clavulanate potassium capacity and its downstream purification steps often drive tighter availability relative to broader penicillin-class supply, but constraints depend on the plant portfolio and market region.
-
Do suppliers differ by dosage form (tablets vs pediatric suspensions)?
Yes. Suspension and chewable formulations usually increase CMO involvement due to formulation and excipient complexity.
-
What procurement documentation matters most for qualification?
GMP evidence, batch release processes, change control support, and the ability to align impurity profiles and specifications to the target market.
-
What contract clauses reduce supply disruption risk?
Multi-site coverage, inventory buffering, tight change-control governance, and predefined replacement-supply triggers.
References
[1] FDA. Drugs@FDA: product and application information for amoxicillin/clavulanate-containing products. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] EMA. European public assessment reports (EPARs) and product information for amoxicillin/clavulanate medicines. https://www.ema.europa.eu/en/medicines
[3] WHO. WHO prequalification of medicines program (context for supplier quality frameworks). https://extranet.who.int/pqweb/
